Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott pays $170 million for PanGenetics' anti-NGF antibody

This article was originally published in Scrip

Executive Summary

Abbott will pay $170 million up front to acquire a Phase I nerve growth factor (NGF) antibody from the Dutch antibody company PanGenetics. The deal, which is expected to close by the end of this year, also allows for a further $20 million in future milestone payments to PanGenetics.

You may also be interested in...



INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan

David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.

Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19

Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.

Sanofi’s Latest Credit Facility Offers Win-Win Model For Pharma And Society

French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel